ARTICLE | Company News
Eisai, Halozyme deal
September 28, 2015 7:00 AM UTC
The companies partnered jointly fund a Phase Ib/II trial of Eisai’s breast cancer drug Halaven eribulin mesylate with Halozyme’s PEGPH20 for first-line treatment of HER2-negative metastatic breast c...